Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

Stock Information for PhaseBio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PhaseBio Pharmaceuticals Inc.

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.